top of page

📚 Peer-Reviewed Research

Scientific understanding of Tesamorelin continues to evolve through published clinical and translational research. The studies below represent many of the most influential investigations into its pharmacology, growth hormone stimulation, visceral adipose tissue reduction, hepatic fat, body composition, and metabolic effects.

Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity

Ellis RJ, et al. The Journal of Infectious Diseases. 2025.

This Phase II randomized clinical trial investigated whether Tesamorelin could improve neurocognitive impairment while reducing abdominal adiposity. Researchers observed significant increases in IGF-1 and reductions in waist circumference, although improvements in neurocognitive performance were not significantly different from standard care after six months.

Research Focus

  • Neurocognitive Function

  • IGF-1 Signaling

  • Abdominal Adiposity

Study Population
Adults with HIV-associated abdominal obesity.

Direct Article
https://pubmed.ncbi.nlm.nih.gov/39813152/

Efficacy and Safety of Tesamorelin in People with HIV Receiving Integrase Inhibitors

Russo SC, et al. AIDS. 2024.

This randomized study evaluated Tesamorelin in adults receiving modern antiretroviral therapy. Treatment significantly reduced visceral adipose tissue, hepatic fat, and trunk-to-limb fat ratio without reducing subcutaneous fat or significantly worsening glucose metabolism.

Research Focus

  • Visceral Fat

  • Hepatic Fat

  • Body Composition

  • Metabolic Safety

Study Population
Adults with HIV and metabolic dysfunction-associated steatotic liver disease.

Direct Article
https://pubmed.ncbi.nlm.nih.gov/38905488/

Effects of Tesamorelin on Non-Alcoholic Fatty Liver Disease in HIV

Stanley TL, et al. The Lancet HIV. 2019.

This multicenter randomized controlled trial demonstrated significant reductions in hepatic fat fraction after 12 months of Tesamorelin treatment. Investigators also observed slower progression of liver fibrosis compared with placebo.

Research Focus

  • Liver Fat

  • NAFLD

  • Hepatic Steatosis

  • Fibrosis

Study Population
Adults with HIV-associated NAFLD.

Direct Article
https://pubmed.ncbi.nlm.nih.gov/31611038/

Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients with Abdominal Fat Accumulation

Stanley TL, et al. JAMA. 2014.

Researchers examined the effects of Tesamorelin on visceral adipose tissue and hepatic fat over six months. Participants receiving Tesamorelin experienced significant reductions in visceral adiposity and modest improvements in liver fat compared with placebo.

Research Focus

  • Visceral Adipose Tissue

  • Liver Fat

  • Body Composition

Study Population
Adults with HIV-associated abdominal fat accumulation.

Direct Article
https://pubmed.ncbi.nlm.nih.gov/25038357/

Tesamorelin Improves Fat Quality Independent of Changes in Fat Quantity

Lake JE, et al. AIDS. 2021.

This imaging study evaluated adipose tissue quality using CT density measurements. Investigators reported improvements in adipose tissue characteristics independent of reductions in total fat mass.

Research Focus

  • Adipose Tissue Quality

  • Visceral Fat

  • CT Imaging

Study Population
Adults with HIV-associated abdominal adiposity.

Direct Article
https://pubmed.ncbi.nlm.nih.gov/33756511/

Effects of Tesamorelin (TH9507), a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat

Falutz J, et al. Journal of Clinical Endocrinology & Metabolism. 2010.

This pooled analysis of two Phase III clinical trials demonstrated sustained reductions in visceral adipose tissue together with increases in lean body mass and circulating IGF-1. Benefits diminished after discontinuation of therapy.

Research Focus

  • Visceral Fat

  • Lean Body Mass

  • IGF-1

  • Long-Term Treatment

Direct Article
https://pubmed.ncbi.nlm.nih.gov/20554713/

Effects of Tesamorelin, a Growth Hormone-Releasing Factor, in HIV-Infected Patients with Abdominal Fat Accumulation

Falutz J, et al. Journal of Acquired Immune Deficiency Syndromes. 2010.

This placebo-controlled trial demonstrated approximately an 18% reduction in visceral adipose tissue together with improvements in body composition and body image measures.

Research Focus

  • Visceral Fat

  • Body Composition

  • Safety

Direct Article
https://pubmed.ncbi.nlm.nih.gov/20101189/

Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV

Falutz J, et al. The New England Journal of Medicine. 2007.

This landmark clinical trial first established Tesamorelin's ability to stimulate endogenous growth hormone secretion while reducing visceral abdominal fat and increasing circulating IGF-1 concentrations.

Research Focus

  • Growth Hormone Secretion

  • IGF-1

  • Visceral Adipose Tissue

  • Metabolic Effects

Direct Article
https://www.nejm.org/doi/full/10.1056/NEJMoa072375

Recent Review Article

Body Composition, Hepatic Fat, Metabolic, and Safety Outcomes of Tesamorelin in HIV-Associated Lipodystrophy: A Meta-analysis of Randomized Controlled Trials

Badran AS, Helal A, Shata KS, Ayesh H. Obesity Research & Clinical Practice. 2026.

This meta-analysis pooled data from randomized controlled trials evaluating Tesamorelin. Overall, treatment consistently reduced visceral adipose tissue, hepatic fat, waist circumference, and trunk fat while increasing lean body mass. No significant reduction in BMI or subcutaneous fat was observed.

Research Focus

  • Systematic Review

  • Visceral Fat

  • Hepatic Fat

  • Lean Body Mass

  • Safety

Direct Article
https://pubmed.ncbi.nlm.nih.gov/?term=Body+composition+hepatic+fat+metabolic+and+safety+outcomes+of+Tesamorelin+2026

​

Research Disclaimer

The information presented in this Research Library is provided for educational and scientific reference purposes only and is based on published peer-reviewed research. Research findings continue to evolve, and investigational compounds may not be approved for clinical use. All Pearland Peptides products are supplied For Research Use Only and are not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease.

bottom of page